Edesa Biotech Prices $25 Million Equity Offering
Edesa Biotech has priced a public offering expected to raise approximately $25 million in gross proceeds. The company plans to issue 3.87 million common shares along with accompanying warrants, as well as pre-funded warrants for up to an additional 675,000 common shares. The underwritten offering is part of Edesa's strategy to strengthen its financial position and support ongoing operations or future growth initiatives. The transaction highlights investor interest in the company’s development pipeline within the biotechnology sector.
